Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia
dc.contributor.author | Friese, Christopher R. | en_US |
dc.contributor.author | Earle, Craig C. | en_US |
dc.contributor.author | Magazu, Lysa S. | en_US |
dc.contributor.author | Brown, Jennifer R. | en_US |
dc.contributor.author | Neville, Bridget A. | en_US |
dc.contributor.author | Hevelone, Nathanael D. | en_US |
dc.contributor.author | Richardson, Lisa C. | en_US |
dc.contributor.author | Abel, Gregory A. | en_US |
dc.date.accessioned | 2011-04-07T18:52:21Z | |
dc.date.accessioned | 2011-04-07T18:52:21Z | |
dc.date.available | 2012-05-14T20:40:08Z | en_US |
dc.date.issued | 2011-04-01 | en_US |
dc.identifier.citation | Friese, Christopher R.; Earle, Craig C.; Magazu, Lysa S.; Brown, Jennifer R.; Neville, Bridget A.; Hevelone, Nathanael D.; Richardson, Lisa C.; Abel, Gregory A. (2011). "Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia." Cancer 117(7): 1470-1477. <http://hdl.handle.net/2027.42/83467> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/83467 | |
dc.description.abstract | BACKGROUND: Little is known about the patterns of care relating to the diagnosis of chronic lymphocytic leukemia (CLL), including the use of modern diagnostic techniques such as flow cytometry. METHODS: The authors used the SEER-Medicare database to identify subjects diagnosed with CLL from 1992 to 2002 and defined diagnostic delay as present when the number of days between the first claim for a CLL-associated sign or symptom and SEER diagnosis date met or exceeded the median for the sample. The authors then used logistic regression to estimate the likelihood of delay and Cox regression to examine survival. RESULTS: For the 5086 patients analyzed, the median time between sign or symptom and CLL diagnosis was 63 days (interquartile range [IQR] = 0-251). Predictors of delay included age ≥75 (OR 1.45 [1.27-1.65]), female gender (OR 1.22 [1.07-1.39]), urban residence (OR 1.46 [1.19 to 1.79]), ≥1 comorbidities (OR 2.83 [2.45-3.28]) and care in a teaching hospital (OR 1.20 [1.05-1.38]). Delayed diagnosis was not associated with survival (HR 1.11 [0.99-1.25]), but receipt of flow cytometry within thirty days before or after diagnosis was (HR 0.84 [0.76-0.91]). CONCLUSIONS: Sociodemographic characteristics affect diagnostic delay for CLL, although delay does not seem to impact mortality. In contrast, receipt of flow cytometry near the time of diagnosis is associated with improved survival. Cancer 2011. © 2010 American Cancer Society. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Nursing Business and Health System, University of Michigan School of Nursing, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Institute for Clinical Evaluative Sciences and University of Toronto, Toronto, Ontario, Canada | en_US |
dc.contributor.affiliationother | Division of Hematology/Oncology, Children's Hospital, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Center for Outcomes and Policy Research, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Surgery, Brigham and Womens' Hospital, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia | en_US |
dc.contributor.affiliationother | Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts ; Center for Outcomes and Policy Research, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts ; Fax: (617) 632-2270 ; Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, 44 Binney Street, Smith 271, Boston, MA 02115 | en_US |
dc.identifier.pmid | 21425148 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/83467/1/25655_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.25655 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.